Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars

Viatris Inc. (NASDAQ:VTRS) connected Thursday, released information from Phase 3 survey evaluating the contraceptive efficacy and information of XULANE LO debased dose play dermal spot of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per time successful women of childbearing potential.
In this study, XULANE LO…

This communicative appeared connected benzinga.com, 2025-05-08 18:55:36.